Advertisement
the title of the release changed to, "Barr Announces Approval of GenericPamidronate Disodium Injection, 30mg/10mL, 60mg/10mL and 90mg/10mL" from,"Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and90mg/mL Injectable";
Advertisement
the first sentence of the first paragraph of the release changed to, "BarrPharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, PLIVALachema a.s., has received final approval from the U.S. Food and DrugAdministration (FDA) for its generic version of Hospira's Pamidronate DisodiumInjection, 30mg/10mL, 60mg/10mL, and 90mg/10mL." from, "Barr Pharmaceuticals,Inc. (NYSE: BRL) today announced that its subsidiary, PLIVA - Lachema a.s.,has received final approval from the U.S. Food and Drug Administration (FDA)for its generic version of Pfizer Inc.'s Aredia(R) (pamindronate disodium)Injection, 30mg/mL, 60mg/mL, and 90mg/mL.";
the first sentence of the second paragraph of the release changed to,"Barr's generic Pamidronate Disodium Injectable product will compete in amarket that had total annual sales of approximately $21 million for the twelvemonths ended June 2008, based on IMS sales data." from, "Barr's generic Aredia(pamindronate disodium) product will compete in a market that had total annualsales of approximately $21 million for the twelve months ended June 2008,based on IMS sales data."
Complete, corrected release follows:
Barr Announces Approval of Generic Pamidronate Disodium Injection, 30mg/10mL,
60mg/10mL and 90mg/10mL
MONTVALE, N.J., Aug. 20 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals,Inc. (NYSE: BRL) today announced that its subsidiary, PLIVA - Lachema a.s.,has received final approval from the U.S. Food and Drug Administration (FDA)for its generic version of Hospira's Pamidronate Disodium Injection,30mg/10mL, 60mg/10mL, and 90mg/10mL. The Company plans to launch its productin the fourth quarter of calendar 2008. With this approval, Barr's U.S.generic injectable portfolio now totals eight products.
Barr's generic Pamidronate Disodium Injectable product will compete in amarket that had total annual sales of approximately $21 million for the twelvemonths ended June 2008, based on IMS sales data.
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical companythat operates in more than 30 countries worldwide and is engaged in thedevelopment, manufacture and marketing of generic and proprietarypharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. Aholding company, Barr operates through its principal subsidiaries: BarrLaboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and itssubsidiaries. The Barr Group of companies markets more than 120 generic and 27proprietary products in the U.S. and approximately 1,025 products globallyoutside of the U.S. For more information, visit www.barrlabs.com.
Forward-Looking Statements
This communication contains "forward-looking statements" which representthe current expectations and beliefs of management of Barr Pharmaceuticals,Inc. (the "Company") concerning the proposed merger of the Company with BoronAcquisition Corp., a wholly-owned subsidiary of Teva Pharmaceutical IndustriesLtd. (the "merger") and other future events and their potential effects on theCompany. The statements, analyses, and other information contained hereinrelating to the proposed merger, as well as other statements including wordssuch as "anticipate," "believe," "plan," "estimate," "expect," "intend,""w
